Kogulugu

Act Amending the Health Insurance Act and Related Amendments to Other Acts ↗

Introduced:
1 December 2025
Author:
Government (Ministry of Social Affairs) · coalition at introduction: Reform, Eesti 200
Stage
Adopted25 March 2026

The draft amends the Health Insurance Act (Ravikindlustuse seadus) and the Medicinal Products Act (Ravimiseadus). The Health Insurance Fund (Tervisekassa) may fund medicines for ultra-rare diseases by way of exception for individual patients and reimburse standardised extemporaneous (pharmacy-made) medicines; the separate list of diseases is abolished and the criteria for discount rates are moved into the law. Conditions for treatment abroad are tightened and aligned with treatment funded in Estonia, and the duty to notify the State Agency of Medicines (Ravimiamet) is dropped for several goods requiring a special permit. The act takes effect on 1 May 2026.

Changes and additions

  1. Exceptional funding of medicines for ultra-rare diseases

    According to the explanatory memorandum, only medicines for outpatient treatment that were on the medicines list or had no marketing authorisation could be funded by way of exception, so most ultra-rare medicines could not be funded this way. The regular procedure could take 3–13 months, according to the memorandum.
    A patient or their legal representative may ask the Health Insurance Fund (Tervisekassa) to fund, by way of exception, a medicine with a valid Estonian marketing authorisation used for a life-threatening disease, or a chronic disease leading to severe disability, that affects at most five people per million in Estonia. The application must include a decision of an expert committee made up of the treating doctor and at least one specialist in the same field.
  2. Reimbursement of standardised pharmacy-made medicines

    According to the memorandum, patients have so far paid the full price of medicines made in pharmacies.
    Now the Health Insurance Fund may, on the written application of a professional association, cover part of the price of standardised extemporaneous medicines, except the basic co-payment. A new term is added to the Medicinal Products Act: a pharmacy-made medicine with a fixed composition that is entered and coded in the medicines register and given a package code.
  3. Price agreement with the manufacturer

    When the Health Insurance Fund funds a medicine for an ultra-rare disease by way of exception, it concludes, where needed, a fixed-term agreement with the manufacturer or marketing authorisation holder so that costs stay within health insurance funds. According to the memorandum, this allows a lower price to be agreed and risks to be shared.
  4. Abolition of the list of diseases and criteria for discount rates

    According to the memorandum, reimbursing a medicine at a 75 or 100 percent rate required amending both the medicines list and a separate list of diseases set by ministerial regulation. The size of the patient's co-payment was not among the criteria.
    The separate list of diseases is abolished. The discount rate (50, 75 or 100 percent) is set when the medicine is put on the list, based on the opinion of the medicines committee (ravimikomisjon) or the rate of a medicine with the same active substance, and on criteria in the law, including the patient's co-payment per prescription. Special rates for children, pensioners and older people stay the same.
  5. Conditions for treatment abroad

    According to the memorandum, one criterion for reimbursing treatment abroad was a 50 percent probability of achieving the aim of treatment, which the memorandum considers subjective. Cost-effectiveness was not assessed for treatment abroad.
    The probability criterion is dropped and a requirement is added that the service be cost-effective and fit within health insurance funds. The Health Insurance Fund may refuse prior authorisation if the main method of treatment is administering a medicine and this can be done in Estonia. The application must be submitted together with the doctors' assessment.
  6. Composition of the panel for treatment abroad

    According to the memorandum, the assessment could be given by two specialists, one of them the patient's treating doctor, and they could be from the same hospital.
    The assessment is given by three specialists in the relevant field, one of them the patient's treating doctor. They must come from at least two different healthcare providers, unless no other provider in Estonia offers that speciality.
  7. Mark-up cap for pharmacy-made medicines

    According to the memorandum, the statutory mark-up cap applied so far only to industrially made medicines.
    Now the proportional mark-up on a pharmacy-made medicine may not exceed 6,40 euros per prescription either. According to the memorandum, the fixed mark-up for preparation is at the same time to be raised substantially by regulation.
  8. End of notification duty to the State Agency of Medicines

    According to the memorandum, the State Agency of Medicines had to be notified of, among other things, exports and intra-European Economic Area border crossings of active substances, hormones, antibiotics, alkaloids, cells, tissues, organs and blood preparations.
    The notification duty no longer applies to these goods. According to the memorandum, an import licence is still required for imports from third countries and these substances remain goods requiring a special permit.

How the text changed during the proceedings

  • No members, committees or factions of the Riigikogu (Estonian parliament) submitted amendments; opinions came from the Health Insurance Fund, the Estonian Society of Hospital Pharmacists (Eesti Haiglaapteekrite Selts) and the Estonian Pharmacists' Association (Eesti Apteekrite Liit). The Social Affairs Committee (sotsiaalkomisjon) put forward six amendments, all fully accepted.
  • On the Estonian Pharmacists' Association's proposal, reimbursement of standardised extemporaneous medicines was moved to a separate provision: in the introduced text it required a per-patient application with a doctor's opinion, while in the final text a professional association applies.
  • On a committee member's recommendation, the term "ultraharvikravim" (ultra-rare medicine) was replaced by "ultraharvikhaiguse ravim" (medicine for an ultra-rare disease); it was also specified that the medicine must have a valid Estonian marketing authorisation and that the agreement with the manufacturer is fixed-term.
  • On the Health Insurance Fund's proposal, the panel provision was reworded so that specialists need not themselves practise at several healthcare providers, but must come from at least two different providers.
  • Entry into force was moved from 1 March to 1 May 2026.
  • The bracketed specification was removed from the draft's title.

Votes

Voting result

Official decision: Adopted

· ·

By faction
  • Estonia 200Members in total: 13

    ·

    In favour · 10
    • Lauri Hussar
    • Ando Kiviberg
    • Irja Lutsar
    • Juku-Kalle Raid
    • Marek Reinaas
    • Stig Rästa
    • Kadri Tali
    • Peeter Tali
    • Tarmo Tamm
    • Toomas Uibo
    Absent · 3
    • Diana Ingerainen
    • Kalev Stoicescu
    • Tanel Tein
  • Estonian Centre PartyMembers in total: 7

    ·

    In favour · 5
    • Vladimir Arhipov
    • Aleksei Jevgrafov
    • Andrei Korobeinik
    • Anastassia Kovalenko-Kõlvart
    • Aleksandr Tšaplõgin
    Did not vote · 2
    • Vadim Belobrovtsev
    • Lauri Laats
  • Conservative People's Party of EstoniaMembers in total: 10

    ·

    Did not vote · 9
    • Arvo Aller
    • Rain Epler
    • Helle-Moonika Helme
    • Mart Helme
    • Rene Kokk
    • Siim Pohlak
    • Anti Poolamets
    • Evelin Poolamets
    • Varro Vooglaid
    Absent · 1
    • Martin Helme
  • Estonian Reform PartyMembers in total: 37

    ·

    In favour · 34
    • Yoko Alender
    • Anti Haugas
    • Jüri Jaanson
    • Toomas Järveoja
    • Mario Kadastik
    • Liina Kersna
    • Signe Kivi
    • Toomas Kivimägi
    • Mait Klaassen
    • Eerik-Niiles Kross
    • Urmas Kruuse
    • Katrin Kuusemäe
    • Kalle Laanet
    • Hanah Lahe
    • Maris Lauri
    • Mihkel Lees
    • Eero Merilind
    • Marko Mihkelson
    • Õnne Pillak
    • Mati Raidma
    • Valdo Randpere
    • Signe Riisalo
    • Maido Ruusmann
    • Andrus Seeme
    • Pipi-Liis Siemann
    • Timo Suslov
    • Margit Sutrop
    • Aivar Sõerd
    • Kristina Šmigun-Vähi
    • Urve Tiidus
    • Madis Timpson
    • Vilja Toomast
    • Kristo Enn Vaga
    • Mart Võrklaev
    Absent · 3
    • Annely Akkermann
    • Meelis Kiili
    • Luisa Värk
  • Non-affiliated membersMembers in total: 17

    · ·

    In favour · 11
    • Jaak Aab
    • Enn Eesmaa
    • Peeter Ernits
    • Andre Hanimägi
    • Maria Jufereva-Skuratovski
    • Tanel Kiik
    • Leo Kunnas
    • Alar Laneman
    • Henn Põlluaas
    • Kersti Sarapuu
    • Jaak Valge
    Did not vote · 5
    • Kalle Grünthal
    • Züleyxa Izmailova
    • Jaanus Karilaid
    • Ester Karuse
    • Tõnis Mölder
    Absent · 1
    • Ants Frosch
  • IsamaaMembers in total: 8

    · ·

    In favour · 4
    • Aivar Kokk
    • Andres Metsoja
    • Helir-Valdor Seeder
    • Priit Sibul
    Did not vote · 2
    • Tõnis Lukas
    • Mart Maastik
    Absent · 2
    • Lea Danilson-Järg
    • Urmas Reinsalu
  • Social Democratic PartyMembers in total: 9

    · ·

    In favour · 4
    • Anti Allas
    • Helmen Kütt
    • Heljo Pikhof
    • Riina Sikkut
    Did not vote · 1
    • Lauri Läänemets
    Absent · 4
    • Raimond Kaljulaid
    • Madis Kallas
    • Tiit Maran
    • Reili Rand
Sources (Riigikogu documents) (16)

Official page of the bill on the Riigikogu website: proceedings and all documents.